Royal London Asset Management’s Merck MRK Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$348M Sell
2,896,154
-300,997
-9% -$34.7M 0.73% 18
2025
Q4
$337M Sell
3,197,151
-2,720
-0.1% -$255K 0.71% 17
2025
Q3
$269M Sell
3,199,871
-206,475
-6% -$17M 0.58% 26
2025
Q2
$270M Sell
3,406,346
-45,210
-1% -$3.59M 0.62% 21
2025
Q1
$310M Buy
3,451,556
+2,190,512
+174% +$205M 0.73% 21
2024
Q4
$125M Buy
1,261,044
+4,002
+0.3% +$413K 0.31% 60
2024
Q3
$143M Buy
1,257,042
+63,061
+5% +$7.49M 0.35% 56
2024
Q2
$148M Buy
1,193,981
+51,198
+4% +$6.59M 0.38% 54
2024
Q1
$151M Sell
1,142,783
-1,011
-0.1% -$125K 0.38% 55
2023
Q4
$125M Buy
1,143,794
+23,830
+2% +$2.47M 0.36% 57
2023
Q3
$115M Buy
1,119,964
+55,012
+5% +$5.93M 0.37% 55
2023
Q2
$123M Buy
1,064,952
+148,727
+16% +$16.9M 0.4% 50
2023
Q1
$97.5M Buy
916,225
+21,653
+2% +$2.34M 0.39% 52
2022
Q4
$99.2M Buy
894,572
+21,693
+2% +$2.22M 0.44% 45
2022
Q3
$75.2M Sell
872,879
-54,262
-6% -$4.84M 0.38% 51
2022
Q2
$84.7M Buy
927,141
+4,180
+0.5% +$371K 0.39% 54
2022
Q1
$75.7M Buy
922,961
+44,009
+5% +$3.47M 0.3% 64
2021
Q4
$67.4M Sell
878,952
-27,826
-3% -$2.22M 0.25% 79
2021
Q3
$68.1M Sell
906,778
-9,116
-1% -$693K 0.28% 73
2021
Q2
$71.2M Sell
915,894
-59,211
-6% -$4.4M 0.29% 72
2021
Q1
$71.7M Buy
975,105
+8,242
+0.9% +$608K 0.33% 68
2020
Q4
$75.4M Sell
966,863
-51,074
-5% -$3.91M 0.4% 58
2020
Q3
$79.5M Sell
1,017,937
-5,867
-0.6% -$460K 0.48% 45
2020
Q2
$74.4M Sell
1,023,804
-37,622
-4% -$2.83M 0.52% 37
2020
Q1
$77.9M Sell
1,061,426
-7,719
-0.7% -$607K 0.63% 29
2019
Q4
$92.9M Buy
1,069,145
+11,679
+1% +$959K 0.64% 28
2019
Q3
$84.9M Sell
1,057,466
-18,952
-2% -$1.52M 0.64% 28
2019
Q2
$86.1M Sell
1,076,418
-18,028
-2% -$1.38M 0.81% 22
2019
Q1
$86.8M Sell
1,094,446
-78,668
-7% -$5.88M 0.68% 24
2018
Q4
$84.4M Buy
1,173,114
+63,596
+6% +$4.49M 0.74% 24
2018
Q3
$75.1M Sell
1,109,518
-82,851
-7% -$5.28M 0.77% 24
2018
Q2
$69.1M Buy
+1,192,369
New +$67.3M 0.69% 26
2016
Q2
$57.1M Sell
1,039,070
-37,270,963
-97% -$1.98B 0.93% 20
2016
Q1
$691K Buy
38,310,033
+37,189,462
+3,319% +$1.82B 0.99% 17
2015
Q4
$56.9M Buy
1,120,571
+18,344
+2% +$925K 0.88% 25
2015
Q3
$51.9M Buy
+1,102,227
New +$58.6M 0.84% 25
2014
Q4
$524K Buy
952,123
+209,110
+28% +$11.7M 0.99% 20
2014
Q3
$42.1M Buy
743,013
+29,948
+4% +$1.68M 1.06% 19
2014
Q2
$38.1M Sell
713,065
-3,203
-0.4% -$175K 0.87% 22
2014
Q1
$37.8M Sell
716,268
-20,922
-3% -$1.08M 0.88% 21
2013
Q4
$35.1M Sell
737,190
-7,576
-1% -$346K 0.89% 18
2013
Q3
$32.8M Buy
744,766
+4,868
+0.7% +$222K 0.88% 19
2013
Q2
$33.4M Buy
+739,898
New +$33M 0.97% 18

Other funds holding MRK

Royal London Asset Management's MRK Position: Q1 2026 in Review

Royal London Asset Management reduced its Merck (MRK) stake by 9.4% in Q1 2026, selling an estimated $34.7M and leaving 2,896,154 shares worth $348M. The position accounts for 0.73% of the portfolio, ranked #18.

Royal London Asset Management first reported a position in MRK in Q2 2013 and has held it in 43 quarters since. 3,779 funds tracked by Wall St. Rank hold MRK as of Q1 2026.

  • Royal London Asset Management held 2,896,154 shares of Merck worth $348M as of Q1 2026.
  • Royal London Asset Management sold 300,997 Merck shares in Q1 2026, an estimated $34.7M.
  • Merck made up 0.73% of Royal London Asset Management's portfolio in Q1 2026, its #18 holding.
  • Royal London Asset Management first reported a position in Merck in Q2 2013 and has held it in 43 quarters since.
  • 3,779 funds tracked by Wall St. Rank held Merck as of Q1 2026.

Based on Royal London Asset Management's 13F filing for Q1 2026, filed 1 May 2026.